光动力治疗脉络膜新生血管性疾病观察

目的 观察光动力疗法治疗脉络膜新生血管性疾病的临床疗效及安全性.方法 回顾性分析2010年9月至2012年6月在贵阳医学院附属医院眼科门诊采用维替泊芬光动力疗法(PDT)治疗脉络膜新生血管性疾病50例65只眼的临床效果,比较PDT治疗前后的视力、CNV范围、光学相干断层成像(OCT)、荧光素血管造影(FFA)、吲哚青绿血管造影(ICGA)等图像资料.年龄相关性黄斑变性(AMD) 35例50只眼;中心性渗出性脉络膜视网膜病变(CEC)5例5只眼;息肉状脉络膜血管病变(PCV)4例4只眼;病理性近视(PM)5例5只眼;外伤性脉络膜裂伤CNV1例1只眼.结果 全组50例65只眼PDT治疗后随访观察6个月,视力稳定和提高的AMD30只眼(60.00％)、CEC 4只眼(80.00％)、PCV 2只眼(50.00％)、PM 4只眼(80.00％)、脉络膜裂伤CNV 1只眼(100％);视力下降、CNV渗漏有进展的AMD 20只眼(40.00％)、CEC 1只眼(20.00％)、PCV 2只眼(50.00％)、PM 1只眼(20.00％).经ICGA、FFA检查发现CNV复发的30例30只眼,重复治疗2次的10例10只眼, 3次的3例3只眼.重复治疗时间:1个月者1例1只眼,3个月者8例8只眼,6个月者1例1只眼.所有病例均未见严重的不良反应.结论 PDT对治疗继发于不同病因的黄斑CNV安全、有效,可以减轻CNV的渗漏,延缓视力下降,但治疗后仍有复发需反复治疗.     

光动力学治疗脉络膜新生血管的临床观察

目的观察光动力学治疗继发于不同病因的黄斑中心凹下或中心凹旁脉络膜新生血管的疗效和安全性。方法回顾16例16眼经荧光血管造影、吲哚青绿造影证实活动性脉络膜新生血管,继发于老年性黄斑变性4眼,病理性近视6眼和中心性渗出性脉络膜视网膜病变6眼。比较PDT治疗前后最佳矫正视力,散瞳前置镜眼底检查以及荧光血管造影和脉络膜血管造影的资料。典型性为主型CNV14眼,轻微典型性CNV1眼,隐匿性CNV1眼。CNV位于黄斑中心凹下12眼,黄斑中心凹旁4眼。光动力学治疗方案参照TAP制定的标准。结果随访时间:1~14个月,平均(5±4.28)个月。1次治疗14眼,重复治疗2次1眼,3次1眼。最终患眼视力提高8眼,保持不变8眼。FFA检查示CNV渗漏停止1眼,渗漏减少10眼,渗漏无明显减少5眼,渗漏面积较治疗前明显缩小(P<0.05)。CNV复发3眼。仅1例在输液时发生光敏剂渗漏,但未发生光敏反应。治疗后视网膜一过性出血增加3眼。结论光动力学治疗为继发于不同病因的黄斑中心凹下或中心凹旁CNV患者提供一种安全有效的治疗选择。部分患者治疗后短时间内复发,PDT治疗CNV的长期疗效有待进一步观察。     

光动力疗法治疗脉络膜新生血管性疾病后导致的脉络膜低灌注

脉络膜新生血管(CNV)是引起多种眼底疾病视力障碍的主要原因.目前临床上有多种治疗方法,如光动力疗法(PDT)、抗血管内皮生长因子(VEGF)疗法、经瞳孔温热疗法(TTT)等,但都不能彻底治愈CNV,需要重复多次治疗.其中,PDT能特异性封闭CNV,但可引起脉络膜低灌注.就PDT治疗后产生的脉络膜低灌注及其影响和应对措施进行综述,回顾PDT治疗后发生脉络膜低灌注的证据,与临床效果之间的关系,评估联合治疗的作用,讨论使用低照度光动力激光治疗减少低灌注的潜力.     

One-year results after radiotherapy of choroidal neovascularization in age-related macular degeneration

Summary Choroidal neovascularization (CNV) associated with age-related macular degeneration is the major cause of legal blindness in Europe and the USA in patients aged more than 65 years, but Chakravarthy et al. has reported that radiotherapy has a beneficial effect on visual acuity. Methods: Since March 1996 we have treated 56 patients in cooperation with the Department of Radiotherapy at the Technical University in Munich. The total dose with external beam radiotherapy was 16 Gy in 8 fractions, delivered through an anterior oblique axis to spare the lens. Before the treatment and 3, 6 and 12 months after therapy, we performed a standardized visual acuity and contrast-sensitivity test (ETDRS, Pelli Robson Chard) and fluorescin angiography 6 and 12 months after therapy. Results: Twenty-five angiograms showed well-defined CNV and 31 not well-defined CNV. Six months after the treatment 15 patients had stable visual acuity within one line. Twenty-seven patients had lost more than one line of visual acuity. There was no difference between well and not well defined CNV's. One year after treatment the visual acuity remained stable within one line in 4 patients, no patient had an increase of two lines or more and 17 patients lost more then 2 lines of vision. We saw no side effects other than sicca symptoms in 3 patients. Conclusion: In our opinion, these results do not show that radiation treatment has a real beneficial effect on visual acuity. Further randomized studies are needed to demonstrate the efficiency of this treatment for choroidal neovascularization in AMD.      

光动力疗法治疗病理性近视脉络膜新生血管的临床观察

目的 探讨光动力疗法(PDT)治疗病理性近视(PM)黄斑部脉络膜新生血管(cNV)短期的安全性和有效性.方法 回顾经临床眼底检查、FFA和/或ICGA检查及确诊的继发于PM的CNV患者19例(19只眼)行PDT治疗前后的临床资料,对比分析其最佳矫正视力、眼底像、眼底血管造影CNV渗漏、OCT及mf-ERG检查结果.光动力治疗方案参照TAP制定的标准.随访时间为3-6个月.结果 PDT治疗后全部患者视力改善或保持不变,无视力下降者.所有患眼底出血或渗出均减轻.FFA/ICGA检查显示:CNV停止渗漏11只眼,占57.89%;渗漏减少8只,占42.11%.OCT检查显示CNV明显变薄.PDT治疗后1个月mf-ERG3-5环N1、P1波波振幅密度值与治疗前均有显著提高(P＜0.05),3个月时3～4环N1、P1波振幅密度值与治疗前均有显著提高(P＜0.05).结论 病理性近视CNV经PDT治疗短期有效,安全性好,PDT治疗CNV的长期疗效有待进一步观察.     

Long-term results of photodynamic therapy for the treatment of choroidal neovascularization secondary to angioid streaks

Purpose To evaluate the anatomic–functional results and complications associated with the use of photodynamic therapy (PDT) with verteporfin in the treatment of choroidal neovascularization (CNV) secondary to angioid streaks (AS).Methods The authors retrospectively evaluated 10 consecutive patients (10 eyes) with CNV secondary to AS. All patients were treated with standard PDT with verteporfin protocol. The primary outcome to evaluate was the proportion of cases that lost <3 lines of visual acuity (VA) measured on ETDRS charts. Secondary outcomes were changes in the greatest linear dimension (GLD) and in the area of the lesion. Seven previously examined patients were used as a control group.Results The mean duration of follow-up was 18 months (SD 9.2, range 6–36 months). In nine cases CNV was subfoveal and in one case, juxtafoveal. Mean VA was 20/126 at baseline (range 20/40–20/320) and 20/500 at the final examination (range 20/64–20/800). Thiree patients (30%) lost<3 lines of VA. Four patients (40%) lost ≥6 lines of VA. The mean line change was −4.9 lines. The mean GLD went from 2861 μm at baseline (SD 1086.6, range 1350–4300 μm) to 4452 μm at last visit (SD 2564.2, range 1260–9450 μm). The mean area of the lesion was 3.78 mm² at baseline (SD 1.9, range 1.0–5.7 mm²) and 12.1 mm² at the final examination (SD 15.1, range 0.8–50.6 mm²). One patient developed a subfoveal rip of the retinal pigment epithelium. In the control group, the mean duration of follow-up was 15 months (SD 2.4, range 12–18 months). At baseline, the mean VA was 20/160 (range 20/100–20/320) and the mean GLD was 2685 μm (SD 676.8, range 1800–3500 μm). At the last examination, mean VA was 20/640 (range: 20/400–20/800) and mean GLD was 5528 μm (SD 2106.90, range 3500–8000 μm).Conclusion PDT with verteporfin does not seem to be a good treatment for stabilization of VA and lesion size in CNV secondary to AS, although the overall results seem to be slightly better in the group of patients treated with PDT than in the control group.The authors have no financial interest in any product mentioned in this article     

多灶性脉络膜炎并发中心凹下脉络膜新生血管的光动力治疗

目的 观察光动力疗法( PDT)为主的综合疗法对多灶性脉络膜炎(MC)并发脉络膜新生血管(CNV)的疗效.方法 临床确诊为MC并发中心凹下CNV并接受PDT等综合治疗的8例9只眼纳入研究.其中,男性1例1只眼,女性7例8只眼.年龄25～54岁,平均年龄(41.8±10.6)岁.所有患者均进行最佳矫正视力(BCVA)、裂隙灯显微镜、间接检眼镜、荧光素眼底血管造影、光相干断层扫描检查.BCVA为20/333到20/50,转换成最小视角对数(logMAR)后其平均值为0.68±0.32;CNV平均面积为(0.767±0.445) mm2;黄斑中心凹视网膜平均厚度为(355.2±65.2)μm.其中行单纯PDT者4只眼,联合口服糖皮质激素2只眼,玻璃体腔注射抗血管内皮生长因子单克隆抗体bevacizumab(商品名Avastin)者1只眼,后Tenon囊下注射曲安奈德者2只眼.治疗后随访3～22个月,平均随访(14.0±5.7)个月.对比分析治疗前后BCVA、CNV面积和中心凹视网膜厚度.结果 末次复诊时,BCVA为20/250到20/25,logMAR平均值为0.58±0.37,与治疗前比较,差异无统计学意义(t=1.890,P=0.095).其中,3只眼视力提高3行,占33.3％;1只眼视力提高1.5行,占11.1％;4只眼视力稳定,占44.4％;1只眼视力下降1.5行,占11.1％;无下降超过3行者.CNV平均面积为(0.684±0.371) mm2,与治疗前比较,差异无统计学意义(t=0.996,P=o.349).黄斑中心凹视网膜平均厚度为(295.3±79.4)μm,与治疗前比较,差异无统计学意义(t=2.242,P=0.055).结论 PDT为主的综合治疗可有效稳定MC并发CNV患者的视力,尤其是联合抗血管内皮生长因子药物或糖皮质激素后.     

Photodynamic therapy with verteporfin for choroidal neovascularization in patients with angioid streaks

PURPOSE: To evaluate the functional and anatomic outcomes of photodynamic therapy (PDT) for choroidal neovascularization (CNV) in patients with angioid streaks. METHODS: The authors retrospectively evaluated 6 consecutive patients (6 eyes) with CNV secondary to angioid streaks. All patients were treated with standard PDT with verteporfin protocol. Standardized protocol refraction, visual acuity testing, ophthalmologic examination, color photographs, fluorescein angiograms and indocyanin angiograms were used to evaluate the results of PDT with verteporfin. Main outcome measures were visual acuity and CNV size. RESULTS: Their mean age was 61.3+/-5.50 years (range, 53-68 years). Follow-up time ranged from 12 to 38 months with mean of 20.5+/-10.91 months. The mean visual acuity at baseline was 20/100 (range 20/25-20/500), and the mean visual acuity at the last examination was 20/320(range 20/125-counting finger). The mean greatest linear dimension (GLD) at baseline was 2400+/-766.81 micrometer, and the mean GLD at the last examination was 3483+/-444.59 micrometer. CONCLUSIONS: PDT for CNV associated with angioid streaks seemed to slow down but not prevent the progression of the disease and associated visual loss.     

脉络膜新生血管基因治疗新进展

脉络膜新生血管是危害视力的主要病变之一,其发生与新生血管抑制因子和生长因子的失衡有关,尚无有效的治疗方法。脉络膜新生血管的基因治疗为我们提供了一种新的治疗理念,本文对基因治疗的研究进展进行综述。     

Radiotherapy for choroidal neovascularization in age-related macular degeneration. A pilot study using low- versus high-dose photon beam radiation

Purpose: Several pilot studies have indicated that low-dose radiation therapy might have a beneficial effect on the course of choroidal neovascularization (CNV) in age-related macular degeneration (AMD). This study aimed to ascertain whether such treatment might halt the progression of neovascular AMD and whether a low or a high radiation dose should be applied. Patients: The patients comprised some randomized to 0 vs 10 vs 36 Gy of radiation and (after a change of the study protocol became necessary) others who participated in a prospective, controlled non-randomized pilot study. Enclosed were eyes with visual acuity of ≥ 0.1 and ≤ 0.6 revealing a juxta-subfoveal CNV either of the occult type (type 1) or the classic type (isolated or as part of a predominantly occult lesion). Results: Eyes treated with 10 Gy for occult CNV (n = 12) were subject to severe visual loss in 41.6 % of the cases compared to 38.5 % in the control group (n = 13) at 12 months of follow-up. For eyes treated with 10 Gy because of classic CNV, the corresponding figures were 33 % (n = 18) and 57 % (n = 14) respectively. At 18 months of follow-up, the percentages were 63 % and 75 % respectively. Fluorescein angiographic growth of classic and occult CNV could not be halted by 10 Gy, while a temporary growth retardation was observed in cases irradiated with 36 Gy. Conclusion: In the study presented, the natural course of occult CNV could not be improved by irradiation with 10 or 36 Gy. In cases of classic CNV, low-dose irradiation with 10 Gy postponed severe visual loss by a maximum of 18 months. A positive treatment effect was also observed in cases irradiated with 36 Gy; however, a 25 % incidence of radiation retinopathy seems unacceptable.      

Photodynamic therapy: ICG angiographic findings

Purpose: Photodynamic therapy (PDT) has been shown to provide immediate occlusion of choroidal neovascularization (CNV), followed by recurrent leakage after single PDT in the majority of the cases after 3 months. Indocyanine green angiography (ICG-A) was used to evaluate completeness of CNV occlusion, effects on physiological choroid and patterns of CNV recurrence. Methods: ICG-A was performed using a confocal laser scanning ophthalmoscope (HRA) before PDT at 1 week, 4 and 12 weeks following PDT. Twenty patients with single and 10 patients with repeated PDT treatments with administration of benzoporphyrin derivative and radiant exposures between 50 and 150 J/cm² were evaluated. Results: Before PDT well-defined CNV was detectable during early ICG-A in all lesions. Depending on the number of treatments, CNV was absent in early phase ICG-A in 46–83 %. CNV reappeared at week 4 in many and at 12 weeks in 77 (66 %) of the cases. The treated area regularly showed hypofluorescence, which persisted until week 12. The intensity of choroidal hypofluorescence showed wide interindividual variability. Recurrence may originate from persistent feeder vessels. Conclusion: With ICG-A we demonstrated that PDT induces hypofluorescence of CNV and choroid possibly due to perfusion changes or blockade phenomena. Recurrence may be due to reperfusion of the preexisting CNV or regrowth from feeder vessels.      

Treatment frequency and visual outcome in subfoveal choroidal neovascularization related to pathologic myopia treated with photodynamic therapy

Background The purpose of this study was to examine the influence of treatment frequency on visual acuity of patients with PDT treatment for subfoveal predominantly classic CNV related to pathological myopia.Design Retrospective case series.Methods Thirty-seven patients with subfoveal predominantly classic CNV caused by pathologic myopia and treated with PDT were included. All patients received a full ophthalmic examination, including best-corrected visual acuity, slit-lamp biomicroscopy, fundus photography and fluorescein angiography, before first treatment and every 3 months thereafter. Photodynamic therapy was performed according to standard protocol. Main outcome measurements were visual acuity and treatment frequency.Results The number of treatments received was 3.35±1.83 (average: 1–7). In 12 eyes (32.43%); the BCVA was stable or increased during the entire follow-up period. In eight eyes (21.62%), the BCVA decreased and did not return to the baseline values. A transient loss of visual acuity (over 3–9 months) with subsequent improvement in visual function was found in 68% (17 eyes). A gain of three or more lines compared with lowest BCVA was found in 56% (14 eyes). The number of treatments did not correlate with baseline BCVA, greatest linear dimension of CNV at baseline or with the change of BCVA from baseline. In cases with transient worsening of BCVA, the recovery of visual acuity correlated significantly with the number of treatments (r=−0.522, P<0.05; Spearman rank correlation) received.Conclusion Visual acuity recovery correlates with the number of PDT re-treatments; in many cases, an improvement in visual function after temporary decrease of BCVA can be observed after re-treatment according to current treatment guidelines. The number of PDT treatments has no negative effect on the visual outcome in subfoveal CNVs caused by pathological myopia.     

黄斑脉络膜新生血管的PDT与TTT疗效对比观察

目的 比较经瞳孔温热疗法(TTT)与光动力疗法(PDT)治疗黄斑脉络膜新生血管的疗效.方法 对比分析渗出性老年黄斑变性(AMD),特发性脉络膜新生血管,病理性近视.眼底血管样条纹继发黄斑CNV97例101只眼治疗后1个月,3个月的矫正视力(BCVA),眼底荧光血管造影(FFA).治疗前均检杏BCVA、FFA、光学相干断层扫描(OCT),部分病例行吲哚青绿脉络膜血管造影(ICGA).其中PDT治疗52例54只眼,,TTT治疗45例47只眼.结果 PDT与TTT治疗后1月、3月矫正视力比较,PDT治疗组提高2行及2行以上与TTT治疗组比较差异无统计学意义(x2=0.27,P＞0.05,x2=0.034,P＞0.05).PDT治疗后1、3月视力提高或不变(稳定)分别有25只眼(46.2%),20只眼(37%),TTT几治疗后1、3月视力提高或不变分别有14只眼(29.8%),16只眼(34%),治疗后1月两组比较差异有统计学意义(x2=3.96,P＜0.05),治疗后3月两组比较差异无统计学意义(x2=1.78,P＞0.05).典型性或典型性为主性CNV PDT与TTT治疗后矫正视力比较,治疗后1、3月PD个组分别有40%,54%,54%,TTT治疗组分别有12.5%,12.5%PD个组视力提高2行或2行以上.两组比较差异有统计学意义(x2=7.57,P＜0.01,x2=4.14,P＜0.05).隐匿性CNVPDT与TTT治疗后矫正视力比较,治疗后1、3个月,PDT与TTT组视力无提高.治疗后1月PDT治疗组视力不变2只眼,TTT组5只眼,两组比较差异无统计学意义(x2=1.67,P＞0.05).治疗后3月两组视力均下降.PDT与TTT治疗后1、3月CNV渗漏比较,治疗后1月PDT治疗组控制或减轻CNV的荧光渗漏要好于TTT治疗组,两组比较差异有统计学意义(x2=6.64,P＜0.05.治疗后3月比较差异无统计学意义(x2=1.2,P＞0.05).结论 PDT对典型性或典型性为主CNV的治疗,随访短期内(1～3个月)在视力、及CNV渗漏方面明显优于TTT治疗.无论PDT或TTT的单一治疗对隐匿性CNV的视力提高作用不大,对于典犁性CNV或隐匿性CNV可以进行PDT与TTT的交叉治疗,但其疗效仍有待长期随访,并进行多样本及设立对照组观察比较.     

光动力疗法:一种脉络膜新生血管性疾病划时代治疗手段的应用回顾与前景展望

通过光化学反应,破坏病理性血管内皮细胞、形成血栓、导致血管萎缩的光动力疗法(PDT)是首个被证实可以有效控制渗出型老年性黄斑变性(AMD)的治疗方法,从2000年引进我国的12年来,将各种原因引起的黄斑区脉络膜新生血管(CNV)的治疗带入了一个新时代;促进了我们对CNV性疾病机制的认识;为中心性浆液性脉络膜视网膜病变、息肉状脉络膜血管病变、脉络膜血管瘤等视网膜脉络膜病变提供了新的治疗手段.然而,随着新药物和治疗方式的增加,对PDT适应证的掌握,PDT联合治疗的选择和治疗方案的优化等临床研究值得进一步探索;PDT的原理,它与个体基因组的关系以及对血管生长机制的影响等研究更是具有挑战.因此,继续从临床和基础方面探索PDT与疾病的关系,不仅可以指导临床应用,满足眼底病临床工作的现实需求,还可能为进一步揭示以CNV为代表的新生血管性疾病发生、发展规律,了解疾病的本质提供帮助.     

病理性近视合并脉络膜新生血管患者经光动力疗法治疗后的生存质量研究

目的评价病理性近视合并脉络膜新生血管患者(CNV)经光动力疗法(PDT)治疗后的生存质量。方法对24例(24只眼)伴CNV的病理性近视患者进行PDT治疗,并随访1年。对治疗前后病理性近视患者的最佳矫正视力、生存质量进行统计分析。结果治疗1年后,87.5%的患者视力下降小于3行。治疗后,调查量表中有部分视功能有显著改变。结论PDT治疗能有效阻止伴CNV的高度近视所致的视力严重下降,提高患者的生存质量。     

特发性脉络膜新生血管光动力疗法的疗效观察

目的观察光动力疗法（PDT）对特发性脉络膜新生血管（CNV）的治疗效果。方法对61例（61只眼）经荧光素眼底血管造影（FFA）和吲哚氰绿眼底血管造影（ICGA）确诊的特发性CNV患者行PDT治疗,观察比较治疗前后眼底形态、视力、视网膜厚度、FFA和ICGA图像特征。PDT平均治疗次数为1、2次。随访时间为6～36个月,平均19个月。结果末次随访时,61只眼中,有41只眼视力提高（67.2％）,15只眼视力无明显变化（24.6％）,5只眼视力下降（8.2％）。经治疗后所有患眼黄斑出血及渗出均明显减轻。FFA图像显示38只眼的CNV荧光素渗漏完全消失,CNV闭合或瘢痕形成（62．3％）;4只眼CNV部分闭合（6.6％）,14只眼CNV小部分闭合（23．0％）,5只眼CNV复发（8．2％）。6只眼经1次PDT治疗CNV完全闭合,相干光断层扫描或视网膜厚度检查可见黄斑区神经上皮脱离及视网膜水肿消失,随访时间最长3年,未见CNV复发,视力保持稳定。研究结果经多重线性回归分析,表明治疗效果与年龄有关（t=0．476,P=0．016）,即年龄每提高一岁,治疗后视力平均下降0．008（95％CI为0．002～0．015）。结论PDT对特发性CNV有较好的治疗效果,特别对年轻患者效果更好些。（中华腰科杂志,2007,43：509-513）     

光动力疗法联合玻璃体腔曲安奈德注射治疗脉络膜新生血管

目的观察光动力疗法(PDT)联合玻璃体腔曲安奈德(TA)注射治疗老年黄斑变性和病理性近视引起的脉络膜新生血管(CNV)的近期疗效和安全性。方法16例经过视力、眼压、荧光素眼底血管造影(FFA)以及光相干断层扫描(OCT)等检查确诊的CNV患者的16只患眼进行PDT联合玻璃体腔TA注射治疗。其中,渗出型老年黄斑变性14例14只眼,病理性近视2例2只眼。16只眼中,12只眼在PDT治疗后72 h行玻璃体腔TA注射,4只眼在PDT 3个月~1年(平均9个月)后行玻璃体腔TA注射。第1年的平均治疗次数为1.1次。联合治疗后,采用与治疗前相同的条件和检查方法进行随访观察,随访时间3~18个月,平均随访时间18.6个月。对比观察治疗前后患者的最佳矫正视力、眼压、CNV病灶渗漏情况以及黄斑区视网膜厚度变化。结果16只眼中,7只眼视力提高,占43.8%;9只眼视力稳定,占56.2%。FFA显示CNV病灶在联合治疗后渗漏停止或减轻,OCT显示黄斑区视网膜水肿消退或减轻。1只眼暂时性眼压升高,占6.3%。经药物短期治疗后恢复正常。结论PDT联合玻璃体腔TA注射可以安全有效地治疗CNV,延缓视力下降,并且可以减少重复治疗的次数。     

光动力疗法治疗老年性黄斑变性合并脉络膜新生血管的临床观察

目的 观察单次光动力疗法(photodynamic therapy, PDT)治疗渗出型老年性黄斑变性(age-related macular degeneration, AMD)合并脉络膜新生血管(choroidal neovascularization, CNV)的短期治疗效果。 方法 回顾分析经荧光素眼底血管造影(fundus fluorescein angiography, FFA)、吲哚青绿血管造影(indocyanine green angiography,ICGA)和光相干断层成像术(optic coherence tomography, OCT)等检查确诊的30例渗出型AMD患者的35只患眼行PDT治疗前和治疗后1周,1、3个月的临床资料，以视力、FFA、ICGA和OCT检查结果为观察指标，评价PDT对渗出型AMD的短期治疗效果。 结果 治疗后3 个月内有34只眼视力不变或提高，1只眼因出血而视力下降；FFA检查显示有19只眼荧光素渗漏减轻或完全消退；OCT检查显示视网膜水肿和浆液性脱离明显好转。全部患者治疗过程中未发生任何不良反应；治疗后3例患者主诉有一过性视物变暗，2例主诉轻微背痛。 结论 PDT治疗渗出型AMD时，可短期封闭CNV，使渗漏减轻或消退，对视力无损害。 (中华眼底病杂志, 2002, 18: 171-174)     

经瞳孔温热疗法治疗老年性黄斑变性合并中心凹下脉络膜新生血管

目的 观察经瞳孔温热疗法（TTT）治疗老年性黄斑变性（AMD） 合并中心凹下脉络 膜新生血管（CNV）的疗效。 方法 采用半导体810红外激光对荧光素眼 底血管造影（FFA）和吲哚青绿血管造影(ICGA)检查确诊的AMD合并CNV患者47例51只眼进行治疗。其中，隐匿型CNV40例42只眼,经典型CNV7例9只眼；初诊时平均视力为0.12。根据病灶大小选择光斑直径分别为0.8、1、2、3.0 mm；能量相应为120、160、260、360 mW；时间60s。治疗后 每1个月随访复查1次，如有需要，进行重复治疗，治疗次数1~3次。治疗后随访3~33个月，平均随访时间10个月。随访时检查视力、眼底出血和渗出吸收、CNV闭合情况。 结果 治疗眼治疗后均无即刻视力下降或其他不适。末诊时平均视力为0.16，与初诊视力相比，68.6 2%无变化，25.53%增加，7.84%降低。FFA联合ICGA检查显示：治疗后3个月时，隐匿型CNV闭 合率为42.86%, 经典型CNV闭合率为22.22%；6个月时，隐匿型CNV闭合率为73.81%，经典型 CNV闭合率为66.67%。检眼镜检查显示：治疗后3个月，隐匿型CNV42只眼中，出血和（或）渗出部分或全部吸收，并有厚薄不等的机化瘢痕形成；经典型CNV9只眼中7只眼出血和渗出 减轻；1只眼有新出血。治疗后6个月，27只隐匿型CNV眼中，3只眼又见新出血，其中2只眼较快吸收，保持至12个月时无变化；5只经典型CNV眼中，2只眼有新出血，再次治疗后吸收 ，随访16个月病情稳定。19只隐匿型CNV眼随访至6个月以上，5只眼出血消失，5只眼有新出血 。6个月以上的随访中，共有8只眼可见新出血，其CNV复发率占15.6％。 结论 TTT治疗AMD 合并经典型或隐匿型CNV均有一定效果。在较长期随访中,约15.6%的CNV复发，复发患眼经再次治疗仍有好转。 （中华眼底病杂志，2004，20：280-284）     

光动力疗法治疗脉络膜新生血管性疾病的初步临床观察

目的:观察使用维替泊芬光动力疗法(photodynamic thera-py,PDT)治疗年龄相关性黄斑变性(age-related maculardegeneration,AMD)、病理性近视和特发性脉络膜新生血管(choroidal neovascularization,CNV)等3种主要的CNV相关疾病的临床效果。方法:对96例(109眼)经临床确诊的上述CNV患者进行PDT治疗,随访1～24(平均9.4)mo。采用最佳矫正视力、荧光素血管造影、吲哚青绿血管造影、光学相干断层成像等指标,观察治疗前后患者的视功能、CNV病灶大小及渗漏情况、以及视网膜水肿变化等,评价PDT治疗CNV的疗效。结果:本组病例包括AMD42例(54眼),病理性近视17例(18眼),特发性CNV患者37例(37眼)。AMD、病理性近视和特发性CNV的平均治疗次数分别为1.2,1.5和1.2次;视力稳定和提高者各组分别为83.3%,83.3%和86.5%;CNV渗漏停止或减少者各组分别为90.7%,83.3%和89.2%:视网膜水肿减轻者各组分别为77.8%,88.9%和86.5%。除3例AMD患者出现眼部严重不良反应外,未发现其他严重不良反应。结论:PDT可有效地改善或稳定AMD、病理性近视和特发性CNV患者的视功能,控制病变进展,近期随访结果安全有效。